Aprea Therapeutics, Inc. (APRE) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Oncternal Therapeutics, Inc.

Acorda Therapeutics, Inc.

Cosmos Health, Inc.

Galecto, Inc.

Lisata Therapeutics, Inc.

NanoViricides, Inc.

Virios Therapeutics, Inc.

Aprea Therapeutics, Inc.

Acurx Pharmaceuticals, Inc.

Azitra, Inc.

Hepion Pharmaceuticals, Inc.

Why is Aprea Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Aprea Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Aprea Therapeutics, Inc.

-70.19%

-0.96

88.47%

S&P 500

13.68%

0.84

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

8.30%

EBIT Growth (5y)

11.54%

EBIT to Interest (avg)

-25.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.14

Sales to Capital Employed (avg)

0.05

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

42.14%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.74

EV to EBIT

0.37

EV to EBITDA

0.37

EV to Capital Employed

2.44

EV to Sales

-5.06

PEG Ratio

Dividend Yield

ROCE (Latest)

664.96%

ROE (Latest)

-112.01%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET PROFIT(HY)

Higher at USD -6.21 MM

DEBT-EQUITY RATIO (HY)

Lowest at -117.85 %

OPERATING PROFIT(Q)

Highest at USD -3.11 MM

EPS(Q)

Highest at USD -0.47

-12What is not working for the Company

NET SALES(HY)

At USD 0.12 MM has Grown at -86.91%

ROCE(HY)

Lowest at -74.72%

RAW MATERIAL COST(Y)

Grown by 299.84% (YoY

CASH AND EQV(HY)

Lowest at USD 30.25 MM

Here's what is working for Aprea Therapeutics, Inc.

Net Profit

Higher at USD -6.21 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Operating Profit

Highest at USD -3.11 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

EPS

Highest at USD -0.47

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Lowest at -117.85 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Aprea Therapeutics, Inc.

Net Sales

At USD 0.12 MM has Grown at -86.91%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Cash and Eqv

Lowest at USD 30.25 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 299.84% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales